Soleus Capital Management L.P. Has $2.02 Million Stock Holdings in MDxHealth SA (NASDAQ:MDXH)

Soleus Capital Management L.P. trimmed its holdings in shares of MDxHealth SA (NASDAQ:MDXH - Free Report) by 22.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 851,688 shares of the company's stock after selling 253,312 shares during the period. Soleus Capital Management L.P. owned about 1.80% of MDxHealth worth $2,019,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in MDXH. Samjo Management LLC lifted its position in shares of MDxHealth by 130.9% during the 4th quarter. Samjo Management LLC now owns 1,824,312 shares of the company's stock valued at $4,324,000 after acquiring an additional 1,034,312 shares during the last quarter. Perkins Capital Management Inc. raised its position in shares of MDxHealth by 31.6% during the fourth quarter. Perkins Capital Management Inc. now owns 983,475 shares of the company's stock worth $2,331,000 after purchasing an additional 236,100 shares during the period. Northern Trust Corp purchased a new stake in shares of MDxHealth during the fourth quarter valued at $1,033,000. Renaissance Technologies LLC lifted its holdings in shares of MDxHealth by 715.2% during the fourth quarter. Renaissance Technologies LLC now owns 123,100 shares of the company's stock valued at $292,000 after purchasing an additional 108,000 shares during the last quarter. Finally, Northern Right Capital Management L.P. acquired a new position in shares of MDxHealth in the 4th quarter valued at $246,000.

MDxHealth Trading Down 1.4%

MDXH traded down $0.03 during trading on Thursday, reaching $2.06. The company had a trading volume of 62,055 shares, compared to its average volume of 85,951. The firm's 50-day simple moving average is $1.65 and its 200 day simple moving average is $1.85. The company has a debt-to-equity ratio of 3.14, a quick ratio of 1.45 and a current ratio of 1.54. The company has a market cap of $97.41 million, a price-to-earnings ratio of -1.36 and a beta of 1.32. MDxHealth SA has a 12-month low of $1.35 and a 12-month high of $3.50.

MDxHealth (NASDAQ:MDXH - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.06). MDxHealth had a negative return on equity of 1,077.84% and a negative net margin of 49.52%. The firm had revenue of $24.29 million during the quarter, compared to analysts' expectations of $22.62 million. Equities research analysts anticipate that MDxHealth SA will post -1.15 earnings per share for the current year.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.